ReviewJournal of clinical medicine2026
Current Therapies for Breast Cancer: What the Plastic Surgeon Needs to Know.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast reconstruction after mastectomy or breast-conserving surgery requires careful planning that accounts for patient preference, comorbidities, tumor characteristics, and anticipated neoadjuvant or adjuvant therapies. Advances in the treatment of breast cancer have led to evolving recommendations for these therapies, with each influencing not just the complications from surgery but also the long-term outcomes. This narrative review summarizes the current indications for these therapies and their potential impacts on breast reconstruction. Contemporary recommendations for postmastectomy radiation therapy, chemotherapy, immunotherapy, endocrine therapy, and other targeted therapies are explored, with an emphasis placed on perioperative management of systemic therapies and how they may influence reconstructive decision-making. Understanding the nuances of these therapies enables plastic surgeons to be strategic in the timing of reconstruction through individualized planning and can improve reconstructive success. As breast cancer treatment evolves, familiarity with oncologic management is essential for achieving safe, patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.